NewsBenzingaGenmab、ESMO 2026で、再発・転移性頭頸部がんの一次治療におけるPD-L1陽性患者を対象としたペトセムタマブ＋ペムブロリズマブの第2相最新データを発表 Genmab、ESMO 2026で、再発・転移性頭頸部がんの一次治療におけるPD-L1陽性患者を対象としたペトセムタマブ＋ペムブロリズマブの第2相最新データを発表 Benzinga 2026.10.26 11:18 (GMT+0) Open on Benzinga Other news Piper Sandler Maintains Neutral on Farmers & Merchants, Raises Price Target to $39 Longeveron Announces Its ELPIS II Study Of Laromestrocel Failed To Meet Primary Efficacy Endpoint Of Change From Baseline In Right Ventricular Ejection Fraction To Treat Infants With Hypoplastic Left Heart Syndrome Elon Musk's $40 Billion Terrestrial Data Center Pivot Draws Fire From Short Seller Jim Chanos After 'Orbital' IPO Hype: '...Pretty Material $500B Question' Wedbush Maintains Outperform on VeriSign, Raises Price Target to $367 EQT, Range Resources Mega-Merger Set to Create US Gas Juggernaut Wells Fargo Upgrades NorthWestern Energy Group to Overweight, Raises Price Target to $90
Longeveron Announces Its ELPIS II Study Of Laromestrocel Failed To Meet Primary Efficacy Endpoint Of Change From Baseline In Right Ventricular Ejection Fraction To Treat Infants With Hypoplastic Left Heart Syndrome
Elon Musk's $40 Billion Terrestrial Data Center Pivot Draws Fire From Short Seller Jim Chanos After 'Orbital' IPO Hype: '...Pretty Material $500B Question'
